Research animal retirement and lifetime care, now available through Alpha Genesis. Professionally managed lifetime care for retired research primates, with expert social reintroduction into stable outdoor groups led by veterinary staff deeply experienced in laboratory-animal medicine.
Learn moreCapabilities
Efficacy, pharmacokinetic/pharmacodynamic, tolerability, and biodistribution studies in rodent tumor models and NHP translational programs, designed to generate interpretable oncology data under welfare-centered, rigorous in-life conditions.
Oncology drug development requires preclinical data that connects antitumor activity to a mechanistically coherent pharmacological narrative. Efficacy data without exposure-response context, or tolerability data without relevant biomarker monitoring, leaves significant interpretive gaps that regulators and clinical teams notice. Alpha Genesis supports oncology programs with integrated in-life execution that captures the full pharmacological picture.
Rodent models form the backbone of our oncology in-life work, offering the throughput, genetic flexibility, and established tumor model literature needed for candidate screening and proof-of-concept studies. For programs where translational confirmation requires primate physiology, immunology, or drug metabolism, NHP support is available to extend the biological relevance of a preclinical package built for North American and international review.
Animal welfare in oncology studies demands particular attention. Tumor-bearing animals require more frequent clinical monitoring and veterinary engagement throughout the study. Our teams are trained specifically to balance scientific endpoint collection with prompt welfare intervention, with prospective welfare criteria defined in the IACUC-approved protocol.
Small molecule, biologic, and cell therapy programs at biotech and pharma organizations use our rodent and NHP capabilities for efficacy, PK/PD, and tolerability study execution.
I-O programs evaluating checkpoint inhibitors, bispecific antibodies, or CAR-T constructs in syngeneic or humanized systems require careful immune monitoring alongside tumor efficacy readouts.
Antibody-drug conjugate and RNA-based therapeutic programs use tolerability and biodistribution studies to characterize the safety profile before advancing to formalized toxicology.
Academic and industry investigators bridging rodent efficacy to NHP PK or tolerability data use our cross-species program continuity to strengthen translational arguments.
Model selection depends on tumor type, mechanistic questions, immunological context, and regulatory considerations. All models require IACUC review and approval.
Subcutaneous and orthotopic tumor models, syngeneic immunocompetent designs, and select xenograft approaches in rodent systems form the primary platform for oncology efficacy and dose-response studies.
Rat models are used for tolerability, PK profiling, and some tumor models where the species provides scientific or practical advantages over the mouse.
NHP are used for translational PK, tolerability bridging, and immune profiling in oncology programs where primate biology is required for confident translation to the clinic.
African green monkeys are available for translational oncology programs where this species offers scientific or practical advantages for PK and tolerability bridging.
Capuchin monkeys are supported for specialized oncology translational work where a New World primate model is scientifically appropriate.
Additional species, including spider monkeys, pigtail macaques, baboons, and marmosets, are available on request for custom oncology programs. Contact us to discuss species and protocol fit.
Oncology programs demand enhanced clinical monitoring of tumor-bearing animals and prospectively defined welfare endpoints, executed by study directors and veterinary teams trained for the clinical presentations of tumor burden and oncology-drug toxicity. Board-certified veterinarians and 24/7/365 clinical care, paired with preventive medicine and enrichment, protect animal wellbeing under the added physiological demands of tumor models, the welfare basis for credible efficacy and tolerability data in both rodent and NHP work. SOP-driven operations and audit-ready documentation support sponsor and regulatory inspection. AAALAC accreditation, USDA licensure, OLAW assurance (PHS Policy), and IACUC oversight back compliance. GLP and non-GLP study support available, with documentation structured to support submissions to major health authorities worldwide.
Tumor-bearing animals require more intensive welfare monitoring than healthy subjects. Our veterinary team and husbandry staff are trained specifically for the clinical presentations associated with tumor burden and oncology drug toxicity.
Programs that need primate PK or tolerability data to complete their preclinical package can access NHP study support within the same organization that ran their rodent work.
Veterinary staff familiar with oncology-relevant adverse events, weight loss, gastrointestinal toxicity, bone marrow suppression, provide clinical oversight informed by therapeutic context.
Running rodent efficacy and NHP tolerability programs at Alpha Genesis preserves protocol logic, data consistency, and sponsor relationship continuity across the preclinical program.
Oncology development timelines are often compressed. Our dedicated study management teams provide timely updates, flag welfare or data concerns early, and maintain forward momentum.
Experience across government-funded oncology programs and commercial drug development provides operational breadth for programs with diverse regulatory and documentation expectations.
Available tumor models depend on your protocol requirements. We work with sponsors to confirm model availability, cell line procurement logistics, and implantation approach, and we move quickly to get studies underway. Contact us to discuss your specific model.
Whether you need a rodent efficacy and tolerability package or NHP translational bridging data, our team will work with you to design a program that is scientifically rigorous, welfare-centered, and submission-ready.
